- Home
- CRDF vs SPPP Comparison
CRDF vs SPPP Comparison
Compare CRDF & SPPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- SPPP
- Stock Information
- Founded
- CRDF 1999
- SPPP 2011
- Country
- CRDF United States
- SPPP Canada
- Employees
- CRDF N/A
- SPPP N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- SPPP
- Sector
- CRDF Health Care
- SPPP
- Exchange
- CRDF Nasdaq
- SPPP NYSE
- Market Cap
- CRDF 169.6M
- SPPP 172.2M
- IPO Year
- CRDF N/A
- SPPP N/A
- Fundamental
- Price
- CRDF $3.21
- SPPP $11.67
- Analyst Decision
- CRDF Strong Buy
- SPPP
- Analyst Count
- CRDF 5
- SPPP 0
- Target Price
- CRDF $10.50
- SPPP N/A
- AVG Volume (30 Days)
- CRDF 1.2M
- SPPP 183.3K
- Earning Date
- CRDF 08-07-2025
- SPPP 01-01-0001
- Dividend Yield
- CRDF N/A
- SPPP N/A
- EPS Growth
- CRDF N/A
- SPPP N/A
- EPS
- CRDF N/A
- SPPP N/A
- Revenue
- CRDF $587,000.00
- SPPP N/A
- Revenue This Year
- CRDF N/A
- SPPP N/A
- Revenue Next Year
- CRDF N/A
- SPPP N/A
- P/E Ratio
- CRDF N/A
- SPPP N/A
- Revenue Growth
- CRDF N/A
- SPPP N/A
- 52 Week Low
- CRDF $2.01
- SPPP $8.55
- 52 Week High
- CRDF $5.64
- SPPP $11.39
- Technical
- Relative Strength Index (RSI)
- CRDF 44.28
- SPPP 65.14
- Support Level
- CRDF $2.96
- SPPP $11.36
- Resistance Level
- CRDF $3.24
- SPPP $11.66
- Average True Range (ATR)
- CRDF 0.28
- SPPP 0.23
- MACD
- CRDF -0.10
- SPPP -0.01
- Stochastic Oscillator
- CRDF 13.03
- SPPP 69.93
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
About SPPP SPROTT PHYS PLATINUM & PALLADIUM
Sprott Physical Platinum & Palladium Tr invests and holds all of its assets in physical platinum and palladium bullion. The company seeks to provide a secure, convenient, and exchange-traded investment alternative for investors interested in holding physical platinum and palladium bullion without the inconvenience that is typical of a direct investment in physical bullion. The Trust invests mainly in long-term holdings of unencumbered, fully allocated, physical platinum and palladium bullion.